You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 11, November 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, LONDON, APRIL 27 TO APRIL 30, 1987-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (13)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Mechanism of Hormone-Sensitive Breast Cancer Progression on Antiestrogen Therapy

Implications for Treatment and Protocol Planning

Rodney F. Pommier, MD; Eugene A. Woltering, MD; Edward J. Keenan, PhD; William S. Fletcher, MD

Arch Surg. 1987;122(11):1311-1316.


Abstract

• Fifteen patients whose tumors progressed while they received tamoxifen citrate therapy were studied by serial determinations of serum levels of estrone (E1), estradiol (E2), and dehydroepiandrosterone (DHEA) obtained during progression after withdrawal from tamoxifen therapy and total endocrine ablation or suppression. Discontinuation of tamoxifen therapy resulted in reductions of DHEA, E1, and E2 levels by 44%, 49%, and 42%, respectively. Ablation or suppression reduced sex steroids to minimal levels and produced responses in all patients. Elevations of DHEA, E1, and E2 could be provoked by readministering tamoxifen to hypophysectomized and oophorectomized, but not adrenalectomized, patients, indicating that the adrenal gland is the source of these sex steroids. We conclude that tamoxifen stimulates adrenal production of DHEA, which is aromatized to E2 and E2. Buildup of E1 and E2 overwhelms the competitive binding of tamoxifen to the estrogen receptor, resulting in tumor progression.

(Arch Surg 1987;122:1311-1316)



Author Affiliations

From the Department of Surgery, Division of Surgical Oncology, Oregon Health Sciences University, Portland. Dr Pommier is a recipient of the Armand Hammer Travel Award for the 1987 meeting.


Footnotes

Accepted for publication July 16, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 28, 1987.

Reprint requests to the Division of Surgical Oncology, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, Oregon 97201 (Dr Pommier).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.